Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorraine Pelosof

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Oncologist|February 2, 2018
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on SorafenibLorraine Pelosof, Steven Lemery, Sandra Casak, et al.
The Oncologist|May 11, 2021
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with SorafenibMay Tun Saung, Lorraine Pelosof, Sandra Casak, et al.
The Oncologist|December 21, 2020
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based ChemotherapyLorraine Pelosof, May Tun Saung, Martha Donoghue, et al.
Frontiers in Immunology|April 9, 2020
NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNγ Induced GenesLai Xu, Lorraine Pelosof, Rong Wang, et al.
The Journal of Pathology|December 3, 2013
Whole-exome sequencing of pancreatic neoplasms with acinar differentiationYuchen Jiao, Raluca Yonescu, G Johan A Offerhaus, et al.
JHEP Reports : Innovation in Hepatology|May 17, 2023
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinomaDavid J Pinato, Xiaoxue Li, Pallavi Mishra-Kalyani, et al.
The Oncologist|July 1, 2021
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public HealthElaine Chang, Lorraine Pelosof, Steven Lemery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2020
Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung CancerDavid E Gerber, William C Putnam, Farjana J Fattah, et al.
Nature Medicine|May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trialPriscilla Merriam, James J Morrow, Emanuele Mazzola, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practiceDavid J Pinato, Thomas U Marron, Pallavi Shruti Mishra-Kalyani, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Oncologist|February 2, 2018
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on SorafenibLorraine Pelosof, Steven Lemery, Sandra Casak, et al.
The Oncologist|May 11, 2021
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with SorafenibMay Tun Saung, Lorraine Pelosof, Sandra Casak, et al.
The Oncologist|December 21, 2020
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based ChemotherapyLorraine Pelosof, May Tun Saung, Martha Donoghue, et al.
Frontiers in Immunology|April 9, 2020
NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNγ Induced GenesLai Xu, Lorraine Pelosof, Rong Wang, et al.
The Journal of Pathology|December 3, 2013
Whole-exome sequencing of pancreatic neoplasms with acinar differentiationYuchen Jiao, Raluca Yonescu, G Johan A Offerhaus, et al.
JHEP Reports : Innovation in Hepatology|May 17, 2023
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinomaDavid J Pinato, Xiaoxue Li, Pallavi Mishra-Kalyani, et al.
The Oncologist|July 1, 2021
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public HealthElaine Chang, Lorraine Pelosof, Steven Lemery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2020
Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung CancerDavid E Gerber, William C Putnam, Farjana J Fattah, et al.
Nature Medicine|May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trialPriscilla Merriam, James J Morrow, Emanuele Mazzola, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practiceDavid J Pinato, Thomas U Marron, Pallavi Shruti Mishra-Kalyani, et al.
Pageof 2